Apr 4, 2005|
GSK Consumer: Over the years...
GSK Consumer is the market leader in the malted beverages segment with a dominating share of over 65% of the market valued at Rs 13 bn. It's product folio includes brands like 'Horlicks', 'Boost', 'Viva' and 'Maltova'. Let's look at the company's journey over the past 5 years.
GlaxoSmithKline Beecham Consumer Healthcare, is the leader of the malted beverages segment, with its brand 'Horlicks' accounting for nearly half of the malted beverage market. Its other key brand, 'Boost' accounts for about 10% share. Maltova and Viva together account for about 3% of the market. Glaxo's worldwide merger with SmithKline led to the company being rechristened from SmithKline Beecham Consumer Healthcare Ltd. to GSK Consumer Healthcare Limited.
The malted food beverage industry is popularly known as the health beverages sector. Historically, malted beverages have had a strong association with milk, which also explains its strong presence in the southern and eastern regions of the country. These regions suffered from milk deficit and malted beverages positioned themselves as substitutes for milk. The health food drink segment is classified into two categories - white liquid (Horlicks, Viva, Complan, Milo) and brown liquid (chocolate based drinks: Boost, Bournvita, Milo, Complan).
Over the years...
|Operating margin %
|Net profit after Tax(Loss)
From the above table, we infer that GSK Consumer's growth has been sluggish at 3.5% CAGR of the past 5 years. Dependence on other income has increased, which grew at 13% in the period under review. Bottomline has actually shrunk over the past 5 years led by pruning of operating margins.
With no major competition, Horlicks rules South and East India. The skewed consumption pattern of the 40,000 tonnes per annum (tpa) Horlicks reflects this aspect as South and East account for 46% and 49%, respectively, of the total demand. But the situation is slowly changing. A combination of factors like increase in income levels, improved milk availability and aggressive promotions has seen sales of brown drinks going up in the South. The other major players in the malted beverage market are Nestle (Milo), Cadbury (Bourvita), Amul (Nutramul) and Heinz (Complan).
The acquisition of the two brands (Viva, Maltova) for a sum of Rs 863 m from Jagatjit Industries in 2000 has not been in line with the company's expectations. Both brands have in fact, together dropped market share from around 7% share at the time of acquisition, to under 3% currently.
The total market size is estimated to be 82,000 tonnes per annum of which about 65% consists of white beverages. The company has plans for Horlicks to go rural with a 100 gms pack which shows that the company is addressing the rural market in a focused way. The growth rates have been slow so far, hovering around 6% per annum, in terms of volume. However, all said and done, a malted drink is not on the priority list of a rural consumer since milk is his primary source of energy and changing his mindset is a mammoth task. Also, the image of the company has been that of an old man's drink which it is trying to change with the introduction of new variants of 'Horlicks'. Its latest offering is a 'Toffee' flavoured drink for its urban patrons.
The company has recently started to explore the 'Ready to Drink' format (vending machines) to grow its business. This business contributed only Rs 10 m to its revenues in CY04. However, the company has earmarked Rs 700 m for expansion of this format.
The company is a single product dominated company and has not exhibited great skill in launching and sustaining new products. The parent has introduced all the new brands in India through its 100% subsidiary SmithKline Beecham Asia Pvt. Ltd. The subsidiary has well known brands like 'Aquafresh' in oral care segment, 'Eno' and 'Crocin' in the OTC pharma portfolio. GSK receives only the marketing fees of around 5% for these products. Moreover, the parent does not have any significant interest in health beverages. The capacity utilisation levels of the company remain a cause of concern (currently 60%).
If looked closely, the company grew at a CAGR of 11%, 5 years prior to CY00 (i.e. between CY95 to CY99). The management anticipated that this growth would continue and hence it increased its capacity. Also, the company thought that it would become an outsourcing hub for the parent, which did not materialize, resulting in added interest burden, higher depreciation and idle capacity.
The stock is trading at Rs 345, reflecting a P/E of 12.3 times our CY07E earnings and market cap to sales of 1.7x. GSK Consumer has no doubt made some progress in reversing the decline in topline over the past few quarters. The company has also indicated the softening of raw material prices for 2005. We feel that with the introduction of VAT, the company's margins will increase further and with correction in its inventory and introduction of new products, the company is poised for growth. However, despite this, the company is not among our top picks from the FMCG sector, owing to its single product dependence.
More Views on News
Jun 20, 2017
While GSK consumer reported muted revenue growth, volumes are seen to be recovering.
Nov 30, 2016
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
Oct 5, 2016
GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.
Jun 1, 2016
GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.
Feb 15, 2016
GSK Consumer Healthcare announced its results for the quarter ended December 2015. While revenues were up by 2% YoY, profits were higher by 37% YoY.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407